PfizerPFE
PFE
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
42% more first-time investments, than exits
New positions opened: 339 | Existing positions closed: 239
1% more funds holding
Funds holding: 2,871 [Q3] → 2,909 (+38) [Q4]
0.48% more ownership
Funds ownership: 65.34% [Q3] → 65.82% (+0.48%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 40 [Q3] → 40 (+0) [Q4]
7% less capital invested
Capital invested by funds: $108B [Q3] → $100B (-$7.61B) [Q4]
15% less call options, than puts
Call options by funds: $3.27B | Put options by funds: $3.87B
36% less repeat investments, than reductions
Existing positions increased: 918 | Existing positions reduced: 1,444
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$28
12%
upside
Avg. target
$29
14%
upside
High target
$29
16%
upside
2 analyst ratings
0 positive
0%
2 neutral
100%
0 negative
0%
UBS Colin Bristow 33% 1-year accuracy 5 / 15 met price target | 12%upside $28 | Neutral Maintained | 5 Feb 2025 |
Citigroup Andrew Baum 67% 1-year accuracy 4 / 6 met price target | 16%upside $29 | Neutral Maintained | 28 Jan 2025 |
Financial journalist opinion
Based on 66 articles about PFE published over the past 30 days
Negative
Forbes
6 hours ago
Did Pfizer Delay Covid Vaccine Announcement Until After 2020 Election? Here's What We Know.
Federal investigators are investigating claims suggesting Pfizer delayed announcing test results of its Covid vaccine until after the 2020 presidential election, the Wall Street Journal reported, bolstering a claim by President Donald Trump, who has claimed for years the company withheld vaccine results to impact his chances at reelection.
Neutral
Market Watch
8 hours ago
Biotech stocks have been hit hard. Why they're a great value now.
Biotech is one of the U.S. stock market's most unloved sectors. But several indicators suggest that a bottom in sentiment could be near, and that's normally a good time to buy.
Negative
The Motley Fool
9 hours ago
Why Pfizer Is My Largest Healthcare Position
Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't entirely warranted.
Negative
New York Post
21 hours ago
Feds probe tip that Pfizer delayed announcing COVID vaccine's success until after 2020 election: report
The report said GSK's former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.
Negative
Zacks Investment Research
21 hours ago
Here's Why Pfizer (PFE) Fell More Than Broader Market
In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.
Negative
Reuters
23 hours ago
US prosecutors probe tip about timing of Pfizer's COVID vaccine, WSJ reports
Federal prosecutors in Manhattan are probing a claim brought by GSK that Pfizer delayed announcing the success of its COVID-19 vaccine in 2020 until after that year's election, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Neutral
WSJ
1 day ago
U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine
Claim came to the U.S. attorney's office in Manhattan via Pfizer rival GSK.
Negative
Seeking Alpha
2 days ago
Pfizer Is Trading As If It's 2009 Again
Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue decline. Recent acquisitions and product launches in oncology and vaccines strengthen Pfizer's market position and future revenue streams. Despite potential risks like tariffs and drug development delays, Pfizer's current valuation is attractive, resembling 2008-2009 levels.
Positive
Zacks Investment Research
2 days ago
5 Large Drug Stocks to Watch as Industry Recovers
Industry Description
Positive
Zacks Investment Research
3 days ago
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?
Of late, pharmaceutical behemoth Pfizer Inc.'s PFE stock has struggled, but it remains a bargain with generous dividends. Its financials aren't in bad shape either.
Charts implemented using Lightweight Charts™